Fei Liu

Fei Liu has extensive work experience in the field of biology and drug discovery. They started their career as a Postdoctoral Researcher at Drexel University College of Medicine, Baruch S. Blumberg Institute in 2011, where they conducted research on the mechanism of Interferon-alpha in inhibiting hepadnavirus cccDNA transcription and developed HBV capsid inhibitors.

In 2013, Fei Liu joined UCLA as a Postdoctoral Researcher, where they focused on developing targeting strategies for the HGF/c-Met pathway and characterizing DNA methylation profiles in gliomas.

Fei Liu then transitioned to industry and worked at Arbutus Biopharma Corporation from 2016 to 2021. They held the positions of Senior Scientist and later Principal Scientist, contributing to drug target discovery and validation, compound screening, optimization of lead compounds, and preclinical development of an anti-HBV small molecule.

From 2021 to 2022, Fei Liu served as the Head of Virology at Evrys Bio, where they designed and oversaw biology efforts in small molecule drug discovery, supervised a team of researchers, and collaborated with external organizations to support drug discovery and development goals.

Currently, Fei Liu holds the position of Associate Director of Cell Biology & Drug Screening at Seed Therapeutics, starting in 2022.

Fei Liu completed a Bachelor's Degree in Life of Science from Inner Mongolia University from 1999 to 2003. Fei then pursued a Master's Degree in Pharmacology from Beijing Normal University from 2003 to 2006. Later, Fei Liu obtained a Doctor of Philosophy (PhD) in Microbiology and Pharmacology from Peking Union Medical College from 2006 to 2010.